With an eye toward ‘inflection capital’ for biotechs, TPG focuses new fund on clinical POC

After about four years of stress testing its life sciences strategy, TPG is committing itself to the sector with $580 million in total committed capital to invest, including the close of the TPG Life Sciences Innovations Fund.

According to Managing Director Lucian Iancovici, the firm really began to re-engage in the therapeutics space in 2018 to see whether its network and investment platform could generate differentiated returns. The more than 30-year-old alternative investment management firm has over $229 billion in assets under management and a history of investing across healthcare in addition to investments across a broad range of sectors, including tech and real estate...